Stergiou Angelos M. 4
4 · SELLAS Life Sciences Group, Inc. · Filed Feb 3, 2023
Insider Transaction Report
Form 4
Stergiou Angelos M.
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2023-02-02+217,500→ 217,500 totalExercise: $3.34Exp: 2033-02-02→ Common Stock (217,500 underlying) - Award
Common Stock
2023-02-02+58,000→ 219,689 total
Footnotes (2)
- [F1]The Reporting Person received an award of 58,000 restricted stock units on February 2, 2023, which shall vest as follows: (i) 25% on December 1, 2023 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.date.
- [F2]One-quarter (1/4) of the option shares will vest and became exercisable one year from the February 2, 2023 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.